The metastatic breast cancer treatment market has grown rapidly in recent years. It will grow from $17.74 billion in 2023 to $19.95 billion in 2024 at a compound annual growth rate (CAGR) of 12.4%. The growth observed in the historical period can be attributed to advancements in systemic therapies, successful outcomes in clinical trials, improvements in diagnostic tools, and efforts in patient advocacy and education.
The metastatic breast cancer treatment market is expected to see rapid growth in the next few years. It will grow to $30.51 billion in 2028 at a compound annual growth rate (CAGR) of 11.2%. The anticipated growth in the forecast period can be attributed to advancements in targeted therapies, trends in personalized medicine, an increase in incidence rates, and improved global access to innovative therapies. Major trends expected in this forecast period include the use of liquid biopsy for monitoring, patient-centric approaches, enhanced supportive care, expanded access to innovative therapies, and collaborative research initiatives.
The anticipated rise in breast cancer prevalence is set to drive the growth of the metastatic breast cancer treatment market in the foreseeable future. Breast cancer, a type of cancer originating in the cells of the breast, develops as abnormal cells undergo uncontrolled growth, forming tumors. This occurrence is influenced by genetic factors, hormonal imbalances, lifestyle, and environmental elements. Metastatic breast cancer treatment contributes to managing the prevalence of breast cancer, enhancing outcomes, and improving the quality of life for individuals facing advanced-stage disease. As per a September 2023 report from the American Cancer Society, approximately 297,790 women are expected to be diagnosed with invasive breast cancer in the same year, with an additional 55,720 new cases of ductal carcinoma in situ (DCIS) projected. The report also estimates that around 43,700 women will succumb to breast cancer in 2023. Consequently, the increasing prevalence of breast cancer stands as a driving force behind the growth of the metastatic breast cancer treatment market.
The surge in the geriatric population is poised to bolster the growth of the metastatic breast cancer treatment market. The geriatric population, typically defined as individuals aged 65 or older, is witnessing an upward trend, contributing significantly to the demand for metastatic breast cancer treatments. With age being a notable risk factor for developing metastatic breast cancer, addressing the unique needs of this demographic becomes crucial for sustained market growth. As indicated in an October 2022 report from the World Health Organization (WHO), it is projected that by 2030, one out of every six individuals globally will be 60 years old or older. The estimate further predicts that by 2050, there will be 2.1 billion people worldwide falling into this age bracket. Hence, the increase in the geriatric population emerges as a key driver for the growth of the metastatic breast cancer treatment market.
The introduction of advanced therapeutic remedies is a prominent trend gaining traction in the metastatic breast cancer treatment market. Major companies in this market are actively advancing therapeutic remedies as part of their strategy to maintain a competitive position. An example is BDR Pharmaceuticals Internationals Pvt. Ltd., an India-based pharmaceutical company that launched Palbociclib, branded as 'BDPALBO' in India. BDPALBO, a generic version of palbociclib, offers a cost-effective treatment option for patients diagnosed with metastatic breast cancer.
Innovation in product development, particularly monoclonal antibodies (mAbs), is a key focus for major companies operating in the metastatic breast cancer treatment market. Monoclonal antibodies, laboratory-produced molecules mimicking the immune system's ability to combat pathogens, are gaining prominence. Roche Pharma, a Switzerland-based pharmaceutical company, introduced PHESGO in India in May 2022. PHESGO, a groundbreaking formulation, combines two monoclonal antibodies, Perjeta (pertuzumab) and Herceptin (trastuzumab), along with hyaluronidase, providing a streamlined treatment approach for both early and metastatic HER2-positive breast cancer. This innovation aims to enhance treatment efficiency and patient convenience, incorporating the benefits of multiple monoclonal antibodies into a more accessible and patient-friendly delivery method.
In April 2023, Pfizer Inc., a US-based biotechnology and pharmaceutical company, acquired Seagen Inc. for $43 billion. This acquisition enhances Pfizer’s oncology portfolio by incorporating antibody-drug conjugate (ADC) technology for the development of drug programs. Seagen Inc., a US-based biotechnology company, is known for its contributions to metastatic triple-negative breast cancer treatment.
Major companies operating in the metastatic breast cancer treatment market report are Pfizer Inc., AstraZeneca plc, Novartis AG, Gilead Science Inc., Eli Lilly & Co., Merck & Co. Inc., GlaxoSmithKline plc, Johnson & Johnson Services Inc., Sun Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Bayer Aktiengesellschaft ., Bristol-Myers Squibb Company, Boehringer Ingelheim Gmbh, Applied Molecular Genetics Inc., Aslan Pharmaceuticals Pte. Ltd., AbbVie Inc., Eisai Co. ltd., Seattle Genetics Inc., Immunomedics Inc., Genentech Inc., MacroGenics Inc., Daiichi Sankyo Company Lmited, Takeda Pharmaceutical Company Lmited, Sanofi S.A., Celgene Corporation, Exelixis Inc., Array BioPharma Inc., Athenex Inc., BioMarin Pharmaceutical Inc., Clovis Oncology Inc., Cyclacel Pharmaceuticals Inc., Immunovative Therapies Ltd., Inovio Pharmaceuticals Inc., Karyopharm Therapeutics Inc., Mersana Therapeutics Inc., Myriad Genetics Inc., Nektar Therapeutics Inc.
North America was the largest region in the metastatic breast cancer treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global metastatic breast cancer treatment market during the forecast period. The regions covered in the metastatic breast cancer treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the metastatic breast cancer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The main types of metastatic breast cancer treatment include chemotherapy, radiation therapy, biologic-targeted therapy, breast surgery, and hormone therapy. Chemotherapy utilizes drugs designed to kill or inhibit the growth of rapidly dividing cells, including cancer cells. It achieves this by targeting the DNA or essential processes of these cells. In the context of metastatic breast cancer treatment, chemotherapy aims to kill or control cancer cells throughout the body, utilizing specific drugs that circulate in the bloodstream. Various types of molecules, such as monoclonal antibodies, peptides, polymers, small molecules, and gene therapy, are administered through oral or parenteral routes by healthcare facilities such as hospitals, clinics, ambulatory surgical centers, and other end-users.
The metastatic breast cancer treatment market research report provides metastatic breast cancer treatment market statistics, including the metastatic breast cancer treatment industry global market size, regional shares, competitors with a metastatic breast cancer treatment market share, detailed metastatic breast cancer treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the metastatic breast cancer treatment industry. This metastatic breast cancer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The metastatic breast cancer treatment market includes revenues earned by entities by immunotherapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The metastatic breast cancer treatment market is expected to see rapid growth in the next few years. It will grow to $30.51 billion in 2028 at a compound annual growth rate (CAGR) of 11.2%. The anticipated growth in the forecast period can be attributed to advancements in targeted therapies, trends in personalized medicine, an increase in incidence rates, and improved global access to innovative therapies. Major trends expected in this forecast period include the use of liquid biopsy for monitoring, patient-centric approaches, enhanced supportive care, expanded access to innovative therapies, and collaborative research initiatives.
The anticipated rise in breast cancer prevalence is set to drive the growth of the metastatic breast cancer treatment market in the foreseeable future. Breast cancer, a type of cancer originating in the cells of the breast, develops as abnormal cells undergo uncontrolled growth, forming tumors. This occurrence is influenced by genetic factors, hormonal imbalances, lifestyle, and environmental elements. Metastatic breast cancer treatment contributes to managing the prevalence of breast cancer, enhancing outcomes, and improving the quality of life for individuals facing advanced-stage disease. As per a September 2023 report from the American Cancer Society, approximately 297,790 women are expected to be diagnosed with invasive breast cancer in the same year, with an additional 55,720 new cases of ductal carcinoma in situ (DCIS) projected. The report also estimates that around 43,700 women will succumb to breast cancer in 2023. Consequently, the increasing prevalence of breast cancer stands as a driving force behind the growth of the metastatic breast cancer treatment market.
The surge in the geriatric population is poised to bolster the growth of the metastatic breast cancer treatment market. The geriatric population, typically defined as individuals aged 65 or older, is witnessing an upward trend, contributing significantly to the demand for metastatic breast cancer treatments. With age being a notable risk factor for developing metastatic breast cancer, addressing the unique needs of this demographic becomes crucial for sustained market growth. As indicated in an October 2022 report from the World Health Organization (WHO), it is projected that by 2030, one out of every six individuals globally will be 60 years old or older. The estimate further predicts that by 2050, there will be 2.1 billion people worldwide falling into this age bracket. Hence, the increase in the geriatric population emerges as a key driver for the growth of the metastatic breast cancer treatment market.
The introduction of advanced therapeutic remedies is a prominent trend gaining traction in the metastatic breast cancer treatment market. Major companies in this market are actively advancing therapeutic remedies as part of their strategy to maintain a competitive position. An example is BDR Pharmaceuticals Internationals Pvt. Ltd., an India-based pharmaceutical company that launched Palbociclib, branded as 'BDPALBO' in India. BDPALBO, a generic version of palbociclib, offers a cost-effective treatment option for patients diagnosed with metastatic breast cancer.
Innovation in product development, particularly monoclonal antibodies (mAbs), is a key focus for major companies operating in the metastatic breast cancer treatment market. Monoclonal antibodies, laboratory-produced molecules mimicking the immune system's ability to combat pathogens, are gaining prominence. Roche Pharma, a Switzerland-based pharmaceutical company, introduced PHESGO in India in May 2022. PHESGO, a groundbreaking formulation, combines two monoclonal antibodies, Perjeta (pertuzumab) and Herceptin (trastuzumab), along with hyaluronidase, providing a streamlined treatment approach for both early and metastatic HER2-positive breast cancer. This innovation aims to enhance treatment efficiency and patient convenience, incorporating the benefits of multiple monoclonal antibodies into a more accessible and patient-friendly delivery method.
In April 2023, Pfizer Inc., a US-based biotechnology and pharmaceutical company, acquired Seagen Inc. for $43 billion. This acquisition enhances Pfizer’s oncology portfolio by incorporating antibody-drug conjugate (ADC) technology for the development of drug programs. Seagen Inc., a US-based biotechnology company, is known for its contributions to metastatic triple-negative breast cancer treatment.
Major companies operating in the metastatic breast cancer treatment market report are Pfizer Inc., AstraZeneca plc, Novartis AG, Gilead Science Inc., Eli Lilly & Co., Merck & Co. Inc., GlaxoSmithKline plc, Johnson & Johnson Services Inc., Sun Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Bayer Aktiengesellschaft ., Bristol-Myers Squibb Company, Boehringer Ingelheim Gmbh, Applied Molecular Genetics Inc., Aslan Pharmaceuticals Pte. Ltd., AbbVie Inc., Eisai Co. ltd., Seattle Genetics Inc., Immunomedics Inc., Genentech Inc., MacroGenics Inc., Daiichi Sankyo Company Lmited, Takeda Pharmaceutical Company Lmited, Sanofi S.A., Celgene Corporation, Exelixis Inc., Array BioPharma Inc., Athenex Inc., BioMarin Pharmaceutical Inc., Clovis Oncology Inc., Cyclacel Pharmaceuticals Inc., Immunovative Therapies Ltd., Inovio Pharmaceuticals Inc., Karyopharm Therapeutics Inc., Mersana Therapeutics Inc., Myriad Genetics Inc., Nektar Therapeutics Inc.
North America was the largest region in the metastatic breast cancer treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global metastatic breast cancer treatment market during the forecast period. The regions covered in the metastatic breast cancer treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the metastatic breast cancer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The main types of metastatic breast cancer treatment include chemotherapy, radiation therapy, biologic-targeted therapy, breast surgery, and hormone therapy. Chemotherapy utilizes drugs designed to kill or inhibit the growth of rapidly dividing cells, including cancer cells. It achieves this by targeting the DNA or essential processes of these cells. In the context of metastatic breast cancer treatment, chemotherapy aims to kill or control cancer cells throughout the body, utilizing specific drugs that circulate in the bloodstream. Various types of molecules, such as monoclonal antibodies, peptides, polymers, small molecules, and gene therapy, are administered through oral or parenteral routes by healthcare facilities such as hospitals, clinics, ambulatory surgical centers, and other end-users.
The metastatic breast cancer treatment market research report provides metastatic breast cancer treatment market statistics, including the metastatic breast cancer treatment industry global market size, regional shares, competitors with a metastatic breast cancer treatment market share, detailed metastatic breast cancer treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the metastatic breast cancer treatment industry. This metastatic breast cancer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The metastatic breast cancer treatment market includes revenues earned by entities by immunotherapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Metastatic Breast Cancer Treatment Market Characteristics3. Metastatic Breast Cancer Treatment Market Trends and Strategies31. Global Metastatic Breast Cancer Treatment Market Competitive Benchmarking32. Global Metastatic Breast Cancer Treatment Market Competitive Dashboard33. Key Mergers and Acquisitions in the Metastatic Breast Cancer Treatment Market
4. Metastatic Breast Cancer Treatment Market - Macro Economic Scenario
5. Global Metastatic Breast Cancer Treatment Market Size and Growth
6. Metastatic Breast Cancer Treatment Market Segmentation
7. Metastatic Breast Cancer Treatment Market Regional and Country Analysis
8. Asia-Pacific Metastatic Breast Cancer Treatment Market
9. China Metastatic Breast Cancer Treatment Market
10. India Metastatic Breast Cancer Treatment Market
11. Japan Metastatic Breast Cancer Treatment Market
12. Australia Metastatic Breast Cancer Treatment Market
13. Indonesia Metastatic Breast Cancer Treatment Market
14. South Korea Metastatic Breast Cancer Treatment Market
15. Western Europe Metastatic Breast Cancer Treatment Market
16. UK Metastatic Breast Cancer Treatment Market
17. Germany Metastatic Breast Cancer Treatment Market
18. France Metastatic Breast Cancer Treatment Market
19. Italy Metastatic Breast Cancer Treatment Market
20. Spain Metastatic Breast Cancer Treatment Market
21. Eastern Europe Metastatic Breast Cancer Treatment Market
22. Russia Metastatic Breast Cancer Treatment Market
23. North America Metastatic Breast Cancer Treatment Market
24. USA Metastatic Breast Cancer Treatment Market
25. Canada Metastatic Breast Cancer Treatment Market
26. South America Metastatic Breast Cancer Treatment Market
27. Brazil Metastatic Breast Cancer Treatment Market
28. Middle East Metastatic Breast Cancer Treatment Market
29. Africa Metastatic Breast Cancer Treatment Market
30. Metastatic Breast Cancer Treatment Market Competitive Landscape and Company Profiles
34. Metastatic Breast Cancer Treatment Market Future Outlook and Potential Analysis
35. Appendix
Executive Summary
This report provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on metastatic breast cancer treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for metastatic breast cancer treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
Scope
Markets Covered:1) By Therapy Type: Chemotherapy; Radiation Therapy; Biologic Targeted Therapy; Breast Surgery; Hormone Therapy
2) By Molecule Type: Monoclonal Antibody; Peptides; Polymer; Small Molecule; Gene Therapy
3) By Route Of Administration: Oral; Parenteral
4) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers; Other End-Users
Companies Mentioned: Pfizer Inc.; AstraZeneca plc; Novartis AG; Gilead Science Inc.; Eli Lilly & Co.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer Inc.
- AstraZeneca plc
- Novartis AG
- Gilead Science Inc.
- Eli Lilly & Co.
- Merck & Co. Inc.
- GlaxoSmithKline plc
- Johnson & Johnson Services Inc.
- Sun Pharmaceutical Industries Ltd.
- F. Hoffmann-La Roche AG
- Bayer Aktiengesellschaft .
- Bristol-Myers Squibb Company
- Boehringer Ingelheim Gmbh
- Applied Molecular Genetics Inc.
- Aslan Pharmaceuticals Pte. Ltd.
- AbbVie Inc.
- Eisai Co. ltd.
- Seattle Genetics Inc.
- Immunomedics Inc.
- Genentech Inc.
- MacroGenics Inc.
- Daiichi Sankyo Company Lmited
- Takeda Pharmaceutical Company Lmited
- Sanofi S.A.
- Celgene Corporation
- Exelixis Inc.
- Array BioPharma Inc.
- Athenex Inc.
- BioMarin Pharmaceutical Inc.
- Clovis Oncology Inc.
- Cyclacel Pharmaceuticals Inc.
- Immunovative Therapies Ltd.
- Inovio Pharmaceuticals Inc.
- Karyopharm Therapeutics Inc.
- Mersana Therapeutics Inc.
- Myriad Genetics Inc.
- Nektar Therapeutics Inc.
Methodology
LOADING...
